Management of adult soft-tissue sarcoma of the extremities and trunk

References

• Mann GB, Lewis JJ, Brennan MF. Adult soft tissue sarcoma. Aust. N. Z. J. Surg.69(5), 336–343 (1999).
   Google Scholar
• Vezeridis MP, Moore R, Karakousis CP. Metastatic patterns in soft-tissue sarcomas. Arch. Surg.118(8), 915–918 (1983).
   PubMed Web of Science ®Google Scholar
• Lahat G, Lazar A, Lev D. Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg. Clin. North Am.88(3), 451–481, v (2008).
   PubMed Web of Science ®Google Scholar
• Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in malignant peripheral nerve sheath tumors: a comparison between sporadic and neurofibromatosis type-1 associated tumors. Sarcoma DOI: 10.1155/2009/756395 (2009) (Epub ahead of print).
   Google Scholar
• Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N. Engl. J. Med.314(16), 1010–1015 (1986).
   PubMed Web of Science ®Google Scholar
• Pollack R, Brennan M, Lawrence W Jr. Society of Surgical Oncology practice guidelines. Soft-tissue sarcoma surgical practice guidelines. Oncology (Williston Park)11(9), 1327–1332 (1997).
   Google Scholar
• Das P, Kotilingam D, Korchin B et al. High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer109(11), 2323–2333 (2007).
   Google Scholar
• Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol. Biomarkers Prev.5(4), 239–246 (1996).
   PubMed Web of Science ®Google Scholar
• German J, Ellis N. Bloom syndrome. In: The Genetic Basis of Human Cancer. Vogelstein B, Kinzler K (Eds). McGraw Hill, NY, USA, 301–315 (2002).
   Google Scholar
• De Smet S, Vandermeeren L, Christiaens MR et al. Radiation-induced sarcoma: analysis of 46 cases. Acta Chir. Belg.108(5), 574–579 (2008).
   Web of Science ®Google Scholar
• Souba WW, McKenna RJ Jr, Meis J, Benjamin R, Raymond AK, Mountain CF. Radiation-induced sarcomas of the chest wall. Cancer57(3), 610–615 (1986).
   Google Scholar
• Martland HS. Occupational poisoning in manufacture of luminous watch dials. JAMA92, 466–473 (1992).
   Google Scholar
• Davidson T, Westbury G, Harmer CL. Radiation-induced soft-tissue sarcoma. Br. J. Surg.73(4), 308–309 (1986).
   Google Scholar
• Huvos AG, Woodard HQ, Cahan WG et al. Postradiation osteogenic sarcoma of bone and soft tissues. A clinicopathologic study of 66 patients. Cancer55(6), 1244–1255 (1985).
   PubMed Web of Science ®Google Scholar
• Arlen M, Higinbotham NL, Huvos AG, Marcove RC, Miller T, Shah IC. Radiation-induced sarcoma of bone. Cancer28(5), 1087–1099 (1971).
   PubMed Web of Science ®Google Scholar
• Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. Arch. Surg.127(12), 1379–1385 (1992).
   PubMed Web of Science ®Google Scholar
• Hozo I, Miric D, Bojic L et al. Liver angiosarcoma and hemangiopericytoma after occupational exposure to vinyl chloride monomer. Environ. Health Perspect.108(8), 793–795 (2000).
   Google Scholar
• Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer1(1), 64–81 (1948).
   PubMed Web of Science ®Google Scholar
• Schiffman S, Berger A. Stewart-Treves syndrome. J. Am. Coll. Surg.204(2), 328 (2007).
   Google Scholar
• Fraumeni JF, Jr., Vogel CL, Easton JM. Sarcomas and multiple polyposis in a kindred. A genetic variety of hereditary polyposis? Arch. Intern. Med.121(1), 57–61 (1968).
   Google Scholar
• Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA247(19), 2692–2694 (1982).
   PubMed Web of Science ®Google Scholar
• Schuetze SM. Utility of positron emission tomography in sarcomas. Curr. Opin. Oncol.18(4), 369–373 (2006).
   Google Scholar
• Schuetze SM. Imaging and response in soft tissue sarcomas. Hematol. Oncol. Clin. North Am.19(3), 471–487, vi (2005).
   Google Scholar
• McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR Am. J. Roentgenol.184(4), 1293–1304 (2005).
   Google Scholar
• Piperkova E, Mikhaeil M, Mousavi A et al. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin. Nucl. Med.34(3), 146–150 (2009).
   PubMed Web of Science ®Google Scholar
• Benz MR, Czernin J, Allen-Auerbach MS et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin. Cancer Res.15(8), 2856–2863 (2009).
   PubMed Web of Science ®Google Scholar
• Kilpatrick SE, Ward WG, Cappellari JO, Bos GD. Fine-needle aspiration biopsy of soft tissue sarcomas. A cytomorphologic analysis with emphasis on histologic subtyping, grading, and therapeutic significance. Am. J. Clin. Pathol.112(2), 179–188 (1999).
   Google Scholar
• Dupuy DE, Rosenberg AE, Punyaratabandhu T, Tan MH, Mankin HJ. Accuracy of CT-guided needle biopsy of musculoskeletal neoplasms. AJR Am. J. Roentgenol.171(3), 759–762 (1998).
   PubMed Web of Science ®Google Scholar
• Mitsuyoshi G, Naito N, Kawai A et al. Accurate diagnosis of musculoskeletal lesions by core needle biopsy. J. Surg. Oncol.94(1), 21–27 (2006).
   PubMedGoogle Scholar
• Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann. Surg. Oncol.4(5), 425–431 (1997).
   PubMed Web of Science ®Google Scholar
• Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J. Bone Joint Surg. Am.64(8), 1121–1127 (1982).
   PubMed Web of Science ®Google Scholar
• Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J. Bone Joint Surg. Am.78(5), 656–663 (1996).
   PubMed Web of Science ®Google Scholar
• Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am. J. Surg. Pathol.16(3), 213–228 (1992).
   PubMed Web of Science ®Google Scholar
• Trojani M, Contesso G, Coindre JM et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int. J. Cancer33(1), 37–42 (1984).
   PubMed Web of Science ®Google Scholar
• Coindre JM, Trojani M, Contesso G et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer58(2), 306–309 (1986).
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer (US) Soft Tissue Sarcoma. In: American Joint Committee on Cancer Staging Manual. Fleming ID, Cooper JS, Henson DE, (Eds). Lippincott-Raven, PA, USA (1997)
   Google Scholar
• LeVay J, O’Sullivan B, Catton C et al. Outcome and prognostic factors in soft tissue sarcoma in the adult. Int. J. Radiat. Oncol. Biol. Phys.27(5), 1091–1099 (1993).
   PubMed Web of Science ®Google Scholar
• Vraa S, Keller J, Nielsen OS, Sneppen O, Jurik AG, Jensen OM. Prognostic factors in soft tissue sarcomas: the Aarhus experience. Eur. J. Cancer34(12), 1876–1882 (1998).
   PubMedGoogle Scholar
• Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J. Clin. Oncol.14(5), 1679–1689 (1996).
   PubMed Web of Science ®Google Scholar
• Coindre JM, Terrier P, Bui NB et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J. Clin. Oncol.14(3), 869–877 (1996).
   PubMed Web of Science ®Google Scholar
• McKee MD, Liu DF, Brooks JJ, Gibbs JF, Driscoll DL, Kraybill WG. The prognostic significance of margin width for extremity and trunk sarcoma. J. Surg. Oncol.85(2), 68–76 (2004).
   PubMed Web of Science ®Google Scholar
• Ramanathan RC, A’Hern R, Fisher C, Thomas JM. Modified staging system for extremity soft tissue sarcomas. Ann. Surg. Oncol.6(1), 57–69 (1999).
   PubMed Web of Science ®Google Scholar
• Brennan MF. Staging of soft tissue sarcomas. Ann. Surg. Oncol.6(1), 8–9 (1999).
   Google Scholar
• Grobmyer SR, Maki RG, Demetri GD et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann. Oncol.15(11), 1667–1672 (2004).
   PubMed Web of Science ®Google Scholar
• Pezzi CM, Rawlings MS Jr, Esgro JJ, Pollock RE, Romsdahl MM. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer69(8), 2098–2103 (1992).
   PubMedGoogle Scholar
• Yang JC, Chang AE, Baker AR et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol.16(1), 197–203 (1998).
   PubMed Web of Science ®Google Scholar
• Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J. Clin. Oncol.14(3), 859–868 (1996).
   PubMed Web of Science ®Google Scholar
• Stotter AT, A’Hern RP, Fisher C, Mott AF, Fallowfield ME, Westbury G. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer65(5), 1119–1129 (1990).
   PubMed Web of Science ®Google Scholar
• Lindberg RD, Martin RG, Romsdahl MM, Barkley HT Jr. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer47(10), 2391–2397 (1981).
   PubMed Web of Science ®Google Scholar
• Fein DA, Lee WR, Lanciano RM et al. Management of extremity soft tissue sarcomas with limb-sparing surgery and postoperative irradiation: do total dose, overall treatment time, and the surgery-radiotherapy interval impact on local control?. Int. J. Radiat. Oncol. Biol. Phys.32(4), 969–976 (1995).
   PubMed Web of Science ®Google Scholar
• Suit HD, Mankin HJ, Wood WC et al. Treatment of the patient with stage M0 soft tissue sarcoma. J. Clin. Oncol.6(5), 854–862 (1988).
   PubMed Web of Science ®Google Scholar
• Singer S, Corson JM, Gonin R, Labow B, Eberlein TJ. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann. Surg.219(2), 165–173 (1994).
   PubMed Web of Science ®Google Scholar
• Harrison LB, Franzese F, Gaynor JJ, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. Int. J. Radiat. Oncol. Biol. Phys.27(2), 259–265 (1993).
   PubMed Web of Science ®Google Scholar
• Marcus SG, Merino MJ, Glatstein E et al. Long-term outcome in 87 patients with low-grade soft-tissue sarcoma. Arch. Surg.128(12), 1336–1343 (1993).
   PubMed Web of Science ®Google Scholar
• Kawaguchi N, Ahmed AR, Matsumoto S, Manabe J, Matsushita Y. The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin. Orthop. Relat. Res.419), 165–172 (2004).
   Google Scholar
• Rosenberg SA, Tepper J, Glatstein E et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann. Surg.196(3), 305–315 (1982).
   PubMed Web of Science ®Google Scholar
• Ghert MA, Davis AM, Griffin AM et al. The surgical and functional outcome of limb-salvage surgery with vascular reconstruction for soft tissue sarcoma of the extremity. Ann. Surg. Oncol.12(12), 1102–1110 (2005).
   PubMed Web of Science ®Google Scholar
• NIMH/NIH Consensus Development Conference statement. Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel. Am. J. Psychiatry142(4), 469–476 (1985).
   PubMedGoogle Scholar
• Brennan MF, Casper ES, Harrison LB, Shiu MH, Gaynor J, Hajdu SI. The role of multimodality therapy in soft-tissue sarcoma. Ann. Surg.214(3), 328–336 (1991).
   PubMed Web of Science ®Google Scholar
• Brooks AD, Gold JS, Graham D et al. Resection of the sciatic, peroneal, or tibial nerves: assessment of functional status. Ann. Surg. Oncol.9(1), 41–47 (2002).
   Google Scholar
• Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer97(10), 2544–2553 (2003).
   PubMed Web of Science ®Google Scholar
• Gronchi A, Casali PG, Mariani L et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J. Clin. Oncol.23(1), 96–104 (2005).
   PubMed Web of Science ®Google Scholar
• Barr LC, Stotter AT, A’Hern RP. Influence of local recurrence on survival: a controversy reviewed from the perspective of soft tissue sarcoma. Br. J. Surg.78(6), 648–650 (1991).
   PubMed Web of Science ®Google Scholar
• Gustafson P, Rooser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma?. Cancer67(8), 2083–2086 (1991).
   PubMed Web of Science ®Google Scholar
• Noria S, Davis A, Kandel R et al. Residual disease following unplanned excision of soft-tissue sarcoma of an extremity. J. Bone Joint Surg. Am.78(5), 650–655 (1996).
   PubMedGoogle Scholar
• Goodlad JR, Fletcher CD, Smith MA. Surgical resection of primary soft-tissue sarcoma. Incidence of residual tumour in 95 patients needing re-excision after local resection. J. Bone Joint Surg. Br.78(4), 658–661 (1996).
   Google Scholar
• Manoso MW, Frassica DA, Deune EG, Frassica FJ. Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas. J. Surg. Oncol.91(3), 153–158 (2005).
   PubMed Web of Science ®Google Scholar
• Fiore M, Casali PG, Miceli R et al. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Ann. Surg. Oncol.13(1), 110–117 (2006).
   PubMed Web of Science ®Google Scholar
• Pisters PW, Pollock RE, Lewis VO et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann. Surg.246(4), 675–681 (2007).
   Google Scholar
• Herr MJ, Harmsen WS, Amadio PC, Scully SP. Epithelioid sarcoma of the hand. Clin. Orthop. Relat. Res. (431), 193–200 (2005).
   Google Scholar
• Karakousis CP, De Young C, Driscoll DL. Soft tissue sarcomas of the hand and foot: management and survival. Ann. Surg. Oncol.5(3), 238–240 (1998).
   Google Scholar
• Thacker MM, Potter BK, Pitcher JD, Temple HT. Soft tissue sarcomas of the foot and ankle: impact of unplanned excision, limb salvage, and multimodality therapy. Foot Ankle Int.29(7), 690–698 (2008).
   Web of Science ®Google Scholar
• Jyothirmayi R, Sittampalam Y, Harmer C. Soft tissue sarcoma of the hand or foot: conservative surgery and radiotherapy. Sarcoma3(1), 17–24 (1999).
   Google Scholar
• Davis AM, O’Sullivan B, Bell RS et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J. Clin. Oncol.20(22), 4472–4477 (2002).
   PubMed Web of Science ®Google Scholar
• O’Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet359(9325), 2235–2241 (2002).
   PubMed Web of Science ®Google Scholar
• Davis AM, O’Sullivan B, Turcotte R et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother. Oncol.75(1), 48–53 (2005).
   PubMed Web of Science ®Google Scholar
• Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int. J. Radiat. Oncol. Biol. Phys.56(2), 482–488 (2003).
   PubMed Web of Science ®Google Scholar
• Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J. Clin. Oncol.26(20), 3440–3444 (2008).
   PubMed Web of Science ®Google Scholar
• Alektiar KM, Leung D, Zelefsky MJ, Healey JH, Brennan MF. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann. Surg. Oncol.9(1), 48–56 (2002).
   Google Scholar
• Catton C, Davis A, Bell R et al. Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapy. Radiother. Oncol.41(3), 209–214 (1996).
   PubMed Web of Science ®Google Scholar
• Torres MA, Ballo MT, Butler CE et al. Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.67(4), 1124–1129 (2007).
   PubMed Web of Science ®Google Scholar
• Kraybill WG, Harris J, Spiro IJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group trial 9514. J. Clin. Oncol.24(4), 619–625 (2006).
   PubMed Web of Science ®Google Scholar
• Pisters PW, Patel SR, Prieto VG et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J. Clin. Oncol.22(16), 3375–3380 (2004).
   PubMed Web of Science ®Google Scholar
• Rydholm A, Gustafson P, Rooser B et al. Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J. Clin. Oncol.9(10), 1757–1765 (1991).
   PubMed Web of Science ®Google Scholar
• Gibbs CP, Peabody TD, Mundt AJ, Montag AG, Simon MA. Oncological outcomes of operative treatment of subcutaneous soft-tissue sarcomas of the extremities. J. Bone Joint Surg. Am.79(6), 888–897 (1997).
   Google Scholar
• Baldini EH, Goldberg J, Jenner C et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J. Clin. Oncol.17(10), 3252–3259 (1991).
   Google Scholar
• Weir LM, Vanbergeyk AB, Masri BA et al. Local excision without radiation for high-grade soft-tissue sarcoma of the extremity and superficial trunk. Sarcoma4(3), 113–117 (2000).
   Google Scholar
• O’Sullivan B, Ward I, Haycocks T, Sharpe M. Techniques to modulate radiotherapy toxicity and outcome in soft tissue sarcoma. Curr. Treat. Options Oncol.4(6), 453–464 (2003).
   PubMedGoogle Scholar
• Hansen EK, Larson DA, Aubin M et al. Image-guided radiotherapy using megavoltage cone-beam computed tomography for treatment of paraspinous tumors in the presence of orthopedic hardware. Int. J. Radiat. Oncol. Biol. Phys.66(2), 323–326 (2006).
   Google Scholar
• Levine AM, Coleman C, Horasek S. Stereotactic radiosurgery for the treatment of primary sarcomas and sarcoma metastases of the spine. Neurosurgery64(2 Suppl.), A54–A59 (2009).
   Google Scholar
• Crist WM, Anderson JR, Meza JL et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol.19(12), 3091–3102 (2001).
   PubMed Web of Science ®Google Scholar
• Heyn RM, Holland R, Newton WA Jr, Tefft M, Breslow N, Hartmann JR. The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children. Cancer34(6), 2128–2142 (1974).
   PubMed Web of Science ®Google Scholar
• McArthur GA, Demetri GD, van Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium study B2225. J. Clin. Oncol.23(4), 866–873 (2005).
   PubMed Web of Science ®Google Scholar
• Fata F, O’Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer86(10), 2034–2037 (1999).
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer104(2), 361–366 (2005).
   PubMed Web of Science ®Google Scholar
• Olawaiye AB, Morgan JA, Goodman A, Fuller AF Jr, Penson RT. Epithelioid angiosarcoma of the uterus: a review of management. Arch. Gynecol. Obstet.278(5), 401–404 (2008).
   Google Scholar
• Gortzak E, Azzarelli A, Buesa J et al. A randomised Phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur. J. Cancer37(9), 1096–1103 (2001).
   PubMed Web of Science ®Google Scholar
• Eilber FC, Rosen G, Eckardt J et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol.19(13), 3203–3209 (2001).
   PubMed Web of Science ®Google Scholar
• Bramwell V, Rouesse J, Steward W et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma – reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol.12(6), 1137–1149 (1994).
   PubMed Web of Science ®Google Scholar
• Woll P, Van Glabbeke M, Hohenberger P et al. Adjuvant Chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): intermim analysis of a randomized Phase III trial. J. Clin. Oncol.25(20 Suppl. 18S), 547s (2007).
   Google Scholar
• Frustaci S, De Paoli A, Bidoli E et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology65(Suppl. 2), 80–84 (2003).
   PubMed Web of Science ®Google Scholar
• Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol.19(5), 1238–1247 (2001).
   PubMed Web of Science ®Google Scholar
• Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma meta-analysis collaboration. Lancet350(9092), 1647–1654 (1997).
   PubMed Web of Science ®Google Scholar
• Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer113(3), 573–581 (2008).
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Wust P et al. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a Phase III randomised pros. J. Clin. Oncol.25(18S Suppl.), 547s (2007).
   Google Scholar
• Verhoef C, de Wilt JH, Grunhagen DJ, van Geel AN, ten Hagen TL, Eggermont AM. Isolated limb perfusion with melphalan and TNF-α in the treatment of extremity sarcoma. Curr. Treat. Options Oncol.8(6), 417–427 (2007).
   PubMedGoogle Scholar
• Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.57(3), 739–747 (2003).
   PubMed Web of Science ®Google Scholar
• Potter DA, Glenn J, Kinsella T et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J. Clin. Oncol.3(3), 353–366 (1985).
   PubMed Web of Science ®Google Scholar
• Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J. Clin. Oncol.15(2), 646–652 (1997).
   PubMed Web of Science ®Google Scholar
• Catton CN, Swallow CJ, O’Sullivan B. Approaches to local salvage of soft tissue sarcoma after primary site failure. Semin. Radiat. Oncol.9(4), 378–388 (1999).
   Google Scholar
• Singer S, Antman K, Corson JM, Eberlein TJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch. Surg.127(5), 548–553 (1992).
   PubMedGoogle Scholar
• Billingsley KG, Burt ME, Jara E et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann. Surg.229(5), 602–610 (1999).
   PubMed Web of Science ®Google Scholar
• Duda RB, Beatty JD, Kokal WA, Riihimaki DU, Terz JJ. Radiographic evaluation for pulmonary metastases in sarcoma patients. J. Surg. Oncol.38(4), 271–274 (1988).
   Google Scholar
• Sheah K, Ouellette HA, Torriani M, Nielsen GP, Kattapuram S, Bredella MA. Metastatic myxoid liposarcomas: imaging and histopathologic findings. Skeletal Radiol.37(3), 251–258 (2008).
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist10(10), 833–841 (2005).
   PubMed Web of Science ®Google Scholar
• Subramanian S, Wiltshaw E. Chemotherapy of sarcoma. A comparison of three regimens. Lancet1(8066), 683–686 (1978).
   Google Scholar
• Rosen G, Forscher C, Lowenbraun S et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer73(10), 2506–2511 (1994).
   PubMed Web of Science ®Google Scholar
• Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist12(11), 1351–1360 (2007).
   PubMedGoogle Scholar
• Maki RG, Wathen JK, Patel SR et al. Randomized Phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J. Clin. Oncol.25(19), 2755–2763 (2007).
   PubMed Web of Science ®Google Scholar
• Duffaud F, Bui B, Penel N et al. A FNCLCC French Sarcoma Group–GETO multicenter randomized Phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). J. Clin. Oncol.26(Suppl.), 555s (2008).
   Google Scholar
• Cassier PA, Dufresne A, Blay JY, Fayette J. Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther. Clin. Risk Manag.4(1), 109–116 (2008).
   PubMedGoogle Scholar
• Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol.8(7), 595–602 (2007).
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J. Clin. Oncol.23(3), 576–584 (2005).
   PubMed Web of Science ®Google Scholar
• Grosso F, Sanfilippo R, Virdis E et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann. Oncol.20(8), 1439–1444 (2009).
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J. Clin. Oncol.24(33), 5271–5276 (2006).
   PubMed Web of Science ®Google Scholar
• Saylors RL 3rd, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J. Clin. Oncol.19(15), 3463–3469 (2001).
   PubMed Web of Science ®Google Scholar
• Wagner LM, Crews KR, Iacono LC et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin. Cancer Res.10(3), 840–848 (2004).
   PubMed Web of Science ®Google Scholar
• Gardner K, Judson I, Leahy M et al. Activity of cedarinib, a highly potent and seletive VEGF signalling inhibitor, in alveolar soft part sarcoma. J. Clin. Oncol.27(15S Suppl.), 541s (2009).
   Google Scholar
• George S, Blay JY, Casali PG et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur. J. Cancer45(11), 1959–1968 (2009).
   PubMed Web of Science ®Google Scholar
• Maki RG, D’Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol.27(19), 3133–3140 (2009).
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma group (EORTC Study 62043). J. Clin. Oncol.27(19), 3126–3132 (2009).
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Maki RG et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J. Clin. Oncol.27(19), 3148–3153 (2009).
   PubMed Web of Science ®Google Scholar
• Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer100(6), 623–626 (2002).
   PubMed Web of Science ®Google Scholar
• Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol.20(17), 3586–3591 (2002).
   PubMed Web of Science ®Google Scholar
• George S, Merriam P, Maki RG et al. Multicenter Phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J. Clin. Oncol.27(19), 3154–3160 (2009).
   PubMed Web of Science ®Google Scholar
• Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr. Opin. Oncol.18(4), 360–362 (2006).
   PubMed Web of Science ®Google Scholar
• Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin. Investig. Drugs17(12), 1947–1954 (2008).
   PubMed Web of Science ®Google Scholar
• Okuno SH, Mahoney MR, Bailey HH et al. A multicenter Phase 2 consortium (P2C) study of mTOR inhibitor CCI-779 in advanced soft tissue sarcoma (STS). J. Clin. Oncol. (24 Suppl.), 521s (2006).
   Google Scholar
• McCormack P. Surgical resection of pulmonary metastases. Semin. Surg. Oncol.6(5), 297–302 (1990).
   PubMedGoogle Scholar
• Choong PF, Pritchard DJ, Rock MG, Sim FH, Frassica FJ. Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. Acta Orthop. Scand.66(6), 561–568 (1995).
   PubMed Web of Science ®Google Scholar
• Kamstock D, Guth A, Elmslie R et al. Liposome–DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther.13(3), 306–317 (2006).
   PubMed Web of Science ®Google Scholar
• Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer. Res.27(1A), 155–164 (2007).
   PubMed Web of Science ®Google Scholar
• Haldar M, Hedberg ML, Hockin MF, Capecchi MR. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res.69(8), 3657–3664 (2009).
   Google Scholar
• Nishijo K, Chen QR, Zhang L et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res.69(7), 2902–2911 (2009).
   PubMed Web of Science ®Google Scholar